To go back to the main page, click here
| S.No. | Drug Name | Biological Name | Developer | Current Development Phase | Additional Information | Start Date | Completion Date | Source |
| 11 | - | IMF-001 | ImmunoFrontier, Inc. | I | The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers. | 2010 | 2011 | Source |
| 12 | - | Lipovaxin-MM | Lipotek Pty Ltd | I | The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body’s ability to destroy cancer cells in patients with metastatic melanoma. | 2009 | 2011 | Source |
| 13 | - | PSMA/PRAME | MannKind Corporation | I | Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. |
2007 | 2009 | Source |
| 14 | - | MKC1106-MT, MKCC1106-MT | Mannkind Corporation | I | A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas. | 2008 | 2010 | Source |
| 15 | - | MKC1106-MT | Mannkind Corporation | II | The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma | 2010 | 2012 | Source |
| 16 | - | V934/V935 | Merck | I | Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors. |
2008 | 2011 | Source |
| 17 | - | Pegylated Interferon-Alpha 2b | NewLink Genetics | II | The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily). | 2008 | 2011 | Source |
| 18 | - | - | Sanofi-Aventis | II | Terminated Objective was: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment. |
2008 | 2010 | Source |
| 19 | - | AdhTAP | TapImmune | Preclinical | - | - | - | - |
| 20 | - | Dacarbazine (DTIC), Temozolomide (TMZ) | Vical/AnGes | III | Approval possibly by 2013 | 2006 | 2012 | Source |
To go back to the main page, click here